Result Update

search t's Advice, Not Adventu

May 25, 2016

₹ 471

		1000			
Rating matrix					
Rating		: Hol	d		
Target		: ₹4	70		
Target Period		: 15-	18 months		
Potential Upside		: 0%			
What's Change	ed?				
Target			Changed	from ₹ 690	to₹470
EPS FY16P			Changed fr		
EPS FY17E			Changed fr		
EPS FY18E			Changed fr	om ₹ 32.9 t	to₹26.2
Rating			Chang	ed from Bu	y to Hold
Quarterly Perfe	ormanaa				
	Q4FY16	Q4FY15	YoY (%)	Q3FY16	QoQ (%)
Revenue	3,266.5	3,092.7	5.6	3,106.6	5.2
EBITDA	219.0	507.7	-56.9	453.7	-51.7
EBITDA (%)	6.7	16.4	-971 bps	14.6	-790 bps
Net Profit	80.9	259.7	-68.9	343.2	-76.4
Key Financials					
(₹crore)		FY15	FY16P	FY17E	FY18E
Revenues		11345.4	13678.3	16129.4	18477.9
EBITDA		2161.7	2501.1	2761.6	3349.2
Adjusted PAT		1180.8	1505.9	1600.7	2101.3
Adj. EPS (₹)		14.7	18.8	19.9	26.2
Valuation sum	mary	EV1E	FY16E	FV17F	FV10F
PE (x)		FY15 32.0	25.1	FY17E 23.6	FY18E 18.0
Target PE (x)		32.0	25.1	23.6	18.0
EV to EBITDA (x)		17.8	16.7	14.8	11.9
Price to book (x)		3.5	3.2	2.9	2.5
RoNW (%)		10.9	12.7	12.1	14.1
RoCE (%)		13.8	12.1	13.1	16.0
		10.0	12.1	10.1	10.0
Stock data					
Particular					Amount
Market Capitalisa	ntion			₹ 39	763 crore
Debt (FY16P)				₹5	191 crore
Cash (FY16P)					871 crore
EV				₹44	083 crore
52 week H/L (₹)					748/492
Equity capital				₹	161 crore
Face value					₹2
Price performa	nce (%)				
		1M	3M	6M	1Y
Cipla		-7.0	-3.9	-22.5	-26.7
Lupin		-6.0	-16.8	-21.3	-15.6
Sun Pharma		-5.8	-9.6	9.4	-23.1
	-1				
Research Analy	st				

Siddhant Khandekar siddhant.khandekar@icicisecurities.com Mitesh Shah mitesh.sha@icicisecurities.com Nandan Kamat nandan.kamat@icicisecurities.com

Cipla (CIPLA)

One-offs impact margins; blur visibility going ahead

- Revenues grew 5.6% YoY to ₹ 3267 crore, (I-direct estimate: ₹ 3196 crore) on account of 15.8% growth in domestic formulations to ₹ 1258 crore (I-direct estimate:₹ 1140 crore). Export formulations grew 3.2% YoY to ₹ 1744 crore (I-direct estimates: ₹ 1824 crore).
- EBITDA margins decreased 971 bps to 6.7% (I-direct estimate: 17.7%) on account of 1) inventory write-off and reduction, 2) incremental R&D spending and 3) other one-offs. EBITDA de-grew 56.9% YoY to ₹ 219 crore (I-direct estimate: ₹ 565.4 crore).
- Net profit de-grew 68.9% YoY to ₹ 80.9 crore, (I-direct estimate: ₹ 299.1 crore) mainly on account of a poor operational performance.

Products launches, front end shift key for formulation exports growth

Formulation exports constitute \sim 56% of the total revenues. To improve the quality of exports, Cipla has undertaken scores of measures off-late. Partnership deals and participation in global tenders were the growth drivers in the past for exports. The focus has now shifted to front-end model especially for the US and a gradual shift from loss making HIV and other tenders to more lucrative respiratory and other opportunities in US and EU. The acquisition of US based Invagen will strengthen Cipla's transformation from back-end to front-end. Similarly recent acquisitions in Africa and other geographies is testimony to this transformation. We expect export sales to grow at a CAGR of 14.7% to ₹ 11058.6 crore during FY16P-18E. Key drivers will be 1) launch of combination inhalers in the developed markets, 2) incremental product launches in the US 3) Increase ARV tender business 4) Medpro consolidation.

Indian formulations growth backed by continuous new launches

With ~5% market share, Cipla is the second largest player in the domestic formulations market. The Acute, Chronic and sub-chronic revenues for the company stands at 43%, 51% and 6%. Domestic formulations comprise ~37% of total revenues. It commands ~20% market share in the respiratory segment. We expect domestic formulations to grow at a CAGR of 16% during FY16P-18E to ₹ 6881.1 crore driven by improved productivity of the newly inducted field force and incremental product launches.

Product rationalisation to be the key; to impact near term margins

In its quest to transform itself from back end to front end (albeit late) the company has initiated some structural changes at the cost of margins such as 1) higher R&D cost on the back of incremental product filings across geographies, 3) higher staff cost on the back of hiring at the global level and 4) higher front-end and SG&A expenses. These measures are likely to dent the base EBITDA margins in the near to mid-term.

Margins enigma to weigh in the near term; downgrade to HOLD

Q4 results were completely subdued on the profitability front due to multiple one-offs and restructuring in exports business. However, what came as a negative surprise from the management commentary was an exceptionally conservative margin guidance (16-18% for base business for the next 0-3 years). This is despite factoring respiratory and other interesting launches in the developed markets. Frequent restructuring indicates that the management is still some distance away from a sustainable business model. In this backdrop the street is likely to focus only on the profitability aspect. In synch with the guidance we have downgraded our FY17E/18E EPS estimates by 18.3%/20.5% to ₹ 19.9/₹ 26.2. What will add to the misery will be the poor return ratios besides margins and like-to-like peer comparison. Our new target price stands at at ₹ 470 based on 18x (earlier 21x) FY18E EPS of ₹ 26.2.



Variance analysis							
	Q4FY16	Q4FY16E	Q4FY15	Q3FY16	YoY (%)	QoQ (%)	Comments
Revenue	3,266.5	3,195.7	3,092.7	3,106.6	5.6	5.2	YoY growth attributed to $\sim\!\!15\%$ growth in domestic formulations which was partially offset by mere 3.2% growth in export formulations
Raw Material Expenses	1,416.0	1,182.4	1,158.8	1,233.8	22.2	14.8	
Gross Profit	1,850.6	2,013.3	1,933.9	1,872.7	-4.3	-1.2	
Gross Margin (%)	56.7	63.0	62.5	60.3	-588 bps	-363 bps	Gross margins were impacted due to inventory write-off and reduction
Employee Expenses	659.1	591.2	514.7	586.2	28.1	12.4	YoY increase in employee cost mainly due to one-offs
Other Expenditure	972.5	856.7	911.5	832.8	6.7	16.8	
Total Operating Expenditure	3,047.6	2,630.3	2,585.0	2,652.8	17.9	14.9	
EBITDA	219.0	565.4	507.7	453.7	-56.9	-51.7	
EBITDA (%)	6.7	17.7	16.4	14.6	-971 bps	-790 bps	Margins were impacted by write-off and reduction of inventory, higher R&D spend and one-offs
Interest	36.8	50.0	43.4	23.0	-15.2	60.2	
Depreciation	141.4	137.5	135.7	137.5	4.2	2.9	
Other income	54.7	24.9	61.2	79.3	-10.6	-31.0	
PBT before EO	95.5	402.9	389.8	372.6	-75.5	-74.4	
Less: Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	
PBT	95.5	402.9	389.8	372.6	-75.5	-74.4	
Tax	-3.9	88.6	103.0	12.0	PL	PL	Included MAT credit of ~₹ 55 crore in Q4FY16
Tax Rate (%)	-4.1	22.0	26.4	3.2	-3051 bps	-730 bps	
MI & Share of loss/ (gain) asso.	18.5	15.2	27.1	17.4	-31.7	6.4	
Net Profit	80.9	299.1	259.7	343.2	-68.9	-76.4	De-growth was mainly in Sync with EBITDA. Increase in depreciation, interest cost and lower other income was largely offset by tax write-back
Key Metrics							
Domestic	1258.0	1140.3	1086.0	1194.0	15.8	5.4	YoY growth was due to incremental product launches and strong growth in respiratory and other key segments
Export Formulations	1744.0	1823.6	1690.0	1833.0	3.2	-4.9	YoY growth was impacted mainly due to restructuring in Europe and accounting adjustment in South Africa
Export API	204.0	150.3	205.0	143.0	-0.5	42.7	
a a (a)(a) (i)	_						

Source: Company, ICICIdirect.com Research

Change in estimates

onanyo m osumata	3 3						
		FY17E			FY18E		
(₹ Crore)	Old	New	% Change	Old	New	% Change	Comments
Revenues	16,910.8	16,129.4	-4.6	19,382.4	18,477.9	-4.7	Revised our estimates downward due to restructuring in European business and currency impact
EBITDA	3,193.2	2,761.6	-13.5	4,022.4	3,349.2	-16.7	
EBITDA Margin (%)	18.9	17.1	-178 bps	20.8	18.1	-267 bps	Changed as per management guidance
PAT	1,955.4	1,600.7	-18.1	2,641.0	2,101.3	-20.4	Decline mainly in sync with operational performance
EPS (₹)	24.4	19.9	-18.3	32.9	26.2	-20.5	

Source: Company, ICICIdirect.com Research

Assumptions							
			Curr	ent	Earli	ier	Comments
(₹ crore)	FY15	FY16P	FY17E	FY18E	FY17E	FY18E	
Domestic	4,825.0	5,111.0	5,983.6	6,881.1	6,112.8	7,029.7	
							Revised our estimates downward due to restructuring in European business and
Export Formulations	5425.6	7624.8	8988.1	10336.3	9674.0	11125.1	currency impact
API	631.9	779.0	688.0	722.4	631.5	663.1	
	-						



Company Analysis

Formed by Dr KA Hamied way back in 1935, Cipla is one of the oldest ventures set up by an Indian in the pre-independence era. With 34 manufacturing facilities spread over seven different locations, Cipla has a gamut of therapeutic offerings ranging from simple anti-infectives to complex oncology products. The product basket includes ~2000+ products encompassing almost all therapies and over 40 dosage forms. The facilities have been approved by various agencies such as the USFDA, WHO-Geneva, MHRA-UK, TGA-Australia, SUKL-Slovak Republic, APVMA-Australia, MCC-South Africa, PIC-Germany, Danish Medical Agency, ANVISA-Brazil, INVIMAColombia, NDA-Uganda, Department of Health-Canada and MOH-Saudi Arabia, among others. So far, the company has not faced any cGMP issues or import alerts from any regulatory authorities.

Cipla's business model focuses on having marketing partnerships with local companies across the globe. Most partners are large generic players in developed countries. The company has partnership deals with ~22 partners in the US and ~65 in Europe. Cipla has also formed stragic alliances for product development, registration and distribution of its products. For the non-regulated markets, the company has maintained long-standing relationships with non-government organisations and institutions globally. However, recent JVs and buying out front-end companies stakes in majority of its markets shows Cipla's clear intension to shifting its partnership model to own front-end model in almost all markets including the US.

Exports constitute around ~61% of total sales. The company exports both APIs and formulations to more than 170 countries including advanced regions such as the US and Europe. Cipla derives 34% of its export revenues from North and Latin America followed by 33% from Africa, 14% from Europe, 13% from Australasia and 6% from the Middle East.

On the product filing front, Cipla has filed 168 ANDAs and ~200 DMFs with the USFDA cumulatively. It has 90 approved products so far in the US market. As far as other geographies are concerned, the count is ~1000 DMFs for 100 odd APIs. Similarly, ~30 of Cipla's products are pre-qualified for WHO tenders. The company spends ~6% of revenues on R&D.

The company acquired two US-based companies, InvaGen Pharmaceuticals and Exelan Pharmaceuticals. InvaGen Pharma has 40 approved ANDAs, 32 marketed products, and 30 pipeline products which it expects to get approvals over the next four years. The above pipeline also includes five FTFs which represent a market size of ~\$8 billion in revenue by 2018. The transaction is valued at US\$ 550 million and is an all cash deal. The combined revenues of these two companies in CY14 were ~US\$ 200 million (~US\$ 225 million TTM June 2015) with EBITDA margins of ~25%. Its revenue grew at ~20% CAGR over the last 3 years.

In the domestic market, Cipla remains among the top five players, thanks to a gamut of product offerings, which covers almost all therapies built on a network of ~7500 medical representatives (MRs) covering a doctor base of ~5,00,000. As per the latest AIOCD ranking (MAT December 2015), Cipla ranks second with market share of ~5%. Breaking it down further, its ranking in acute therapies stands at 1 with a market share of 4.3%. Similarly, its chronic ranking is 2 with a market share of 6.8%.



Respiratory therapy accounts for $\sim 20\%$ of Cipla's turnover. The company introduced Salbutamol tablets in 1976 and Salbutamol inhaler in 1978 for the first time in India. Since then, Cipla has consistently introduced new products for asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis (AR). More recently, the company did the same in other diseases such as pulmonary arterial hypertension (PAH), lung cancer and idiopathic pulmonary fibrosis (IPF).

Overall we expect revenues to grow at a CAGR of 16.2% in FY16P-18E to ₹ 18477.9 crore driven by incremental product launches in the Europe and other geographies.




Exhibit 1: Revenues to grow at a CAGR of 16.2% in FY16P-18E

Source: Company, ICICIdirect.com Research


Exhibit 2: Consolidated Revenues Break up									
(₹ crore)	FY15	FY16E	FY17E	FY18E					
Domestic	4825.0	5111.0	5983.6	6881.1					
Export APIs	631.9	779.0	688.0	722.4					
Export Formualtions	5425.6	7624.8	8988.1	10336.3					


Source: Company, ICICIdirect.com Research


Formulation exports constitute ~56% of the total revenues. To improve the quality of exports, Cipla has undertaken scores of measures off-late. Partnership deals and participation in global tenders were the growth drivers in the past for exports. The focus has now shifted to front-end model especially for the US and a gradual shift from loss making HIV and other tenders to more lucrative respiratory and other opportunities in US and EU. Recent acquisitions in Africa and other geographies is testimony to this transformation. We expect export sales to grow at a CAGR of 14.7% to ₹ 11058.6 crore during FY16P-18E. Key drivers will be 1) launch of combination inhalers in EU markets, 2) incremental product launches by its partners and increase in own product filings in the US 3) reduced focus on the ARV tender business & at the same time increased focus on PEPFAR like tenders 4) and 4) Medpro consolidation.

With ~5% market share, Cipla is the second largest player in the domestic formulations market. The Acute: Chronic: Sub-chronic ratio for the company stands at 43:51:6. Domestic formulations comprise ~37% of total revenues. It commands ~20% market share in respiratory segment. We expect domestic formulations to grow at a CAGR of 16% during FY16P-18E to ₹ 6881.1 crore driven by improved productivity of the newly inducted field force and incremental product launches.



















Source: Company, ICICIdirect.com Research



Exhibit 6: Trends in quar	terly financia	als									
(₹ crore)	Q4FY14	Q1FY15	Q2FY15	Q3FY15	Q4FY15	Q1FY16	Q2FY16	Q3FY16	Q4FY16	YoY (%)	QoQ. (%)
Net Sales	2445.3	2647.2	2629.8	2624.7	2980.7	3776.8	3361.7	3027.3	3206.7	7.6	5.9
Other Operating Income	90.2	72.8	137.5	140.8	112.0	76.0	90.7	79.3	59.9	-46.5	-24.5
Total Operating Income	2535.6	2720.0	2767.3	2765.5	3092.7	3852.8	3452.4	3106.6	3266.5	5.6	5.2
Raw Material Expenses	1003.5	1025.2	1015.9	989.8	1158.8	1251.6	1216.9	1233.8	1416.0	22.2	14.8
Gross Profit	1532.0	1694.8	1751.4	1775.7	1933.9	2601.2	2235.5	1872.7	1850.6	-4.3	-1.2
Gross Profit Margins	60.4	62.3	63.3	64.2	62.5	67.5	64.8	60.3	56.7	-588 bps	-363 bps
Employee Expenses	427.9	480.0	473.5	505.5	514.7	620.3	585.9	586.2	659.1	28.1	12.4
% of revenues	16.9	17.6	17.1	18.3	16.6	16.1	17.0	18.9	20.2	353 bps	131 bps
Other Expenditure	694.8	673.0	719.4	716.4	911.5	941.9	860.2	832.8	972.5	6.7	16.8
% of revenues	27.4	24.7	26.0	25.9	29.5	24.4	24.9	26.8	29.8	30 bps	296 bps
Total Expenditure	2126.3	2178.2	2208.9	2211.6	2585.0	2813.8	2663.0	2652.8	3047.6	17.9	14.9
EBITDA	409.3	541.8	558.4	553.8	507.7	1039.0	789.4	453.7	219.0	-56.9	-51.7
EBITDA (%)	16.1	19.9	20.2	20.0	16.4	27.0	22.9	14.6	6.7	-971 bps	-790 bps
Interest	34.1	33.3	46.9	44.7	43.4	51.4	50.3	23.0	36.8	-15.2	60.2
Depreciation	105.0	125.4	122.0	121.6	135.7	128.8	134.0	137.5	141.4	4.2	2.9
Other Income	77.5	40.4	23.3	40.7	61.2	48.9	25.9	79.3	54.7	-10.6	-31.0
PBT	347.7	423.5	412.8	428.2	389.8	907.8	631.1	372.6	95.5	-75.5	-74.4
Total Tax	75.3	101.9	100.7	94.4	103.0	250.3	181.2	12.0	-3.9	-103.8	-132.6
PAT before MI	272.4	321.6	312.1	333.7	286.8	657.5	449.9	360.6	99.4	-65.3	-72.4
Minority Interest	11.7	27.0	13.4	5.9	27.1	6.9	18.6	17.4	18.5	-31.7	6.4
Net Profit	260.7	294.6	298.7	327.9	259.7	650.6	431.2	343.2	80.9	-68.9	-76.4
EPS (₹)	3.2	3.7	3.7	4.1	3.2	8.1	5.4	4.3	1.0		

Source: Company, ICICIdirect.com Research

SWOT Analysis

Strengths- Huge product basket, large capacities, relatively clean regulatory record, presence in almost all therapeutic areas, strong balance sheet

Weakness- Late in adopting the front-end model in the US. Frequent restructuring and hit on the margins on account of his.

Opportunities- The US Generics space. Well poised to establish dominance in niche therapies like Respiratory, Oncology etc.

Threats- Increased USFDA scrutiny across the globe regarding cGMP issues and consolidation in the US pharmacy space. Recently Form 483s were issued to company's Indore and InvaGen's plants.

Concall Highlights

- The impact of the DPCO and FDC ban in FY16 on the domestic portfolio was in the range of 2-3% of sales.
- The company plans to launch 15-17 products in the US (including 5-7 through InvaGen) and file 20-25 ANDAs in FY17. The filings will include respiratory and oncology products. The company has filed 168 cumulative ANDAs with the USFDA, of which 90 have been approved.
- The company has completed InvaGen acquisition and most of its products have been transitioned from Camber to Cipla. The company expects InvaGen's annual run rate of ~US\$ 250 million to sustain going ahead. Top three products account for 30-35% of InvaGen's revenues.
- The management has indicated that InvaGen's 483 observations have been closed.
- Post acquisition, the contribution of US sales to the overall revenues is ~20% and the company expects it to increase further.
- In FY16, the company filed for 7 products in the US, 19 in Europe and over 700 in International markets.
- The company has over 200 formulation development projects underway, of which top 50 projects cover addressable market of US\$ 30 billion, based on innovative sales. Of these, the US



accounts for 26 projects. Further inhalation and injectable delivery forms account for 25 of the 50 top projects.

- In FY16, the company has executed six in-licensing deals in oncology, respiratory and dermatology segments in domestic market. It also initiated five incremental innovation projects, of which three would be commercialized in FY17.
- The company's tender business in South Africa grew 60% YoY in FY16. Currently, it has ~5% market share in South African private market and is the third largest generics player in the market.
- The company accelerated execution plan for in-house biologics clinical trial for Bevacizumab (angiogenesis inhibitor) and proofof-concept (POC) for 2-3 other products.
- R&D spend for FY16 was 6.5% of sales and 8.2% for Q4FY16. The company gave R&D guidance of 8% of sales for FY17.
- The company gave guidance of mid-teens revenue growth and EBITDA growth of 15-20% on its base business. Base EBITDA margins are expected to be 16-18% going forward.
- The company plans clinical trials and filing for its MDI (Metered Dose Inhaler) device in the US in FY17.
- The company's capex for FY16 was ~8% of sales. It guided for similar % of capex for FY17.

Exhibit 7: Adjustments in Q4FY16

Adjustments (% of sales)	Q4FY16
Non-moving inventory write-off	~1.3%
Complexity reduction – restructuring and rationalization	~2.1%
Other one-offs (primarily regulatory changes)	~1.3%
Incremental R&D spending	~2.2%
Inventory reduction	~2.1%


Source: Company, ICICIdirect.com Research

Exhibit 8: Major Facilities		
Location	Segment	Regulatory Approvals
Bengaluru — Virgonagar, India	API	USFDA, UKMHRA
Bengaluru– Bommasandra, India	API	USFDA
Patalganga, India	API & Formulations	USFDA, UKMHRA
Kurkumbh, India	Formulations	USFDA, UKMHRA
Goa, India	Formulations	USFDA, UKMHRA
Baddi, India	Formulations	
Indore, India	Formulations	USFDA, UKMHRA
Sikkim, India	Formulations	
Kampala, Uganda	Formulations	
Durban, South Africa	Formulations	
Satara, Maharashtra, India	API	
Courses Commence ICICIdianat and Baserand		



Valuation

Q4 results were completely subdued on the profitability front due to multiple one-offs and restructuring in exports business. However, what came as a negative surprise from the management commentary was an exceptionally conservative margin guidance (16-18% for base business for the next 0-3 years). This is despite factoring respiratory and other interesting launches in the developed markets. Frequent restructuring indicates that the management is still some distance away from a sustainable business model. In this backdrop the street is likely to focus only on the profitability aspect. In synch with the guidance we have downgraded our FY17E/18E EPS estimates by 18.3%/20.5% to ₹ 19.9/₹ 26.2. What will add to the misery will be the poor return ratios besides margins and like-to-like peer comparison. Our new target price stands at at ₹ 470 based on 18x (earlier 21x) FY18E EPS of ₹ 26.2.









Exhibit 10: One year forward PE of company vs. BSE Healthcare Index

Source: Company, ICICIdirect.com Research

Exhibit 1	Exhibit 11: Valuation									
	Revenues	Growth	EPS	Growth	P/E	EV/EBITDA	RoNW	RoCE		
	(₹ crore)	(%)	(₹)	(%)	(x)	(X)	(%)	(%)		
FY15	11345	12	14.7	-15	32.0	17.8	10.9	13.8		
FY16P	13678	21	18.8	28	25.1	16.7	12.7	12.1		
FY17E	16129	18	19.9	6	23.6	14.8	12.1	13.1		
FY18E	18478	15	26.2	31	18.0	11.9	14.1	16.0		





Source: Bloomberg, Company, ICICIdirect.com Research

Key events	
Date	Event
Mar-09	Sells contraceptive brand I-pill to Piramal Healthcare for ₹ 95 crore
May-10	Approves to acquire two manufacturing facilities located in Sikkim and Pune for ₹ 82 crore from its contract manufacturers
Feb-13	Plans to buy its South Africa's marketing partner Cipla Medpro for ₹ 2700 crore
Feb-14	Enters into a JV with existing business partners in Morocco – Societe Marocaine De Cooperation Pharmaceutique ("Cooper Pharma") and The Pharmaceutical Institute (PHI). As per the agreement, Cipla (EU) Limited will hold 60% stake in the JV
May-14	Company signs a definitive agreement to invest USD 1.5 million in Chase Pharmaceuticals Corporation Inc, US ("Chase") to acquire 14.6% stake
Jun-14	Company signs a definitive agreement for US\$ 14 million with the Company's existing Sri Lankan distributor to aquire of 60% stake in a new company
Jun-14	Company signs a definitive agreement to acquire a 51% stake in a pharmaceuticals manufacturing and distribution business in Yemen (in turn owned by a UAE based parent company).
Jul-14	Company, has acquired 75% stake in Mabpharm Private Limited ("Mabpharm"). Mabpharm has now become 100% subsidiary of the Company.
Oct-14	Company signs a definitive agreement with its existing Iranian distributor to set up a manufacturing facility in Iran. The total contribution from the Company over the next 3 years will include machinery, equipment, technical know-how and is expected to be approx INR 225 crore for a 75% stake.
Oct-14	Cipla Medpro announces collaboration with Teva to exclusively market Teva's product protfolio in South Africa
Nov-14	Cipla announces a distribution agreement with Serum Institute of India for affordable paediatric vaccines in Europe
Dec-14	Cipla Medpro, the third largest pharmaceutical company in South Africa, announces it has been awarded R2 billion share of the South African Government's 2015-17 National ARV tender. The contract is effective from the 1 st of April 2015 and will run for a period of three years.
Feb-15	Cipla (EU) enters into a joint venture (JV) agreement with Company's existing business partners in Morocco - Societe Marocaine De Cooperation Pharmaceutique ("Cooper Pharma") and The Pharmaceutical Institute (PHI).
May-15	Acquires 51% stake in Uganda-based Quality Chemicals (QCL) for US\$30 million (around ₹ 191 crore). The turnover of the company in FY14 was US\$ 4.98 million
Feb-16	Cipla completed acquisitions of InvaGen and Exelan, companies it purchased last September in an all cash transaction worth US\$ 550 million
Source: Compa	ny, ICICIdirect.com Research

Top 1	op 10 Shareholders							rn			
Rank	Investor Name	Latest Filing Date	% 0/S	Position (%)	Position Chan	(in %)	Mar-15	Jun-15	Sep-15	Dec-15	Mar-16
1	Hamied (Yusuf K)	31-Mar-16	20.8	166.7m	0.0m	Promoter	36.8	36.8	36.8	37.6	37.5
2	Life Insurance Corporation of India	31-Mar-16	6.0	48.1m	6.7m	FII	25.4	18.3	22.5	23.1	21.1
3	Ahmed (Sophie)	31-Mar-16	5.7	46.0m	0.0m	DII	9.8	16.0	11.7	12.4	13.7
4	Hamied (Mustafa Khwaja)	31-Mar-16	4.9	39.7m	0.0m	Others	28.0	28.9	29.0	26.9	27.7
5	ICICI Prudential Asset Management Co. Ltd.	31-Mar-16	4.3	34.4m	10.3m						
6	OppenheimerFunds, Inc.	31-Mar-16	1.4	11.3m	-0.3m						
7	Hamied (Kamil)	31-Mar-16	1.4	10.9m	0.0m						
8	Vontobel Asset Management, Inc.	31-Mar-16	1.3	10.1m	-9.1m						
9	Hamied (Rumana)	31-Mar-16	1.2	9.9m	0.0m						
10	Vaziralli (Samina)	31-Mar-16	1.2	9.9m	0.0m						

Source: Reuters, ICICIdirect.com Research

Recent Activity					
Buys			Sells		
Investor name	Value (\$)	Shares	Investor name	Value (\$)	Shares
ICICI Prudential Asset Management Co. Ltd.	80.0m	10.3m	Hamied (Farida Yusuf)	-361.4m	-41.9m
Abu Dhabi Investment Authority	65.9m	8.5m	Vontobel Asset Management, Inc.	-70.4m	-9.1m
Life Insurance Corporation of India	51.8m	6.7m	Unigestion	-8.4m	-0.9m
Birla Sun Life Asset Management Company Ltd.	18.8m	2.3m	APG Asset Management	-5.5m	-0.6m
Causeway Capital Management LLC	12.6m	1.6m	JM Financial Asset Management Pvt. Ltd.	-3.9m	-0.5m
Source: Reuters, ICICIdirect.com Research					



Financial summary

Profit and loss statement				₹ Crore
(Year-end March)	FY15	FY16P	FY17E	FY18E
Revenues	11,345.4	13,678.3	16,129.4	18,477.9
Growth (%)	12.3	20.6	17.9	14.6
Raw Material Expenses	4,189.7	5,118.4	5,846.7	6,721.3
Gross Profit	7,155.7	8,559.9	10,282.7	11,756.6
Employee Expenses	1,973.7	2,451.5	2,862.7	3,233.6
Other Expenditure	3,020.4	3,607.3	4,658.3	5,173.8
Total Operating Expenditure	9,183.7	11,177.2	13,367.7	15,128.7
EBITDA	2,161.7	2,501.1	2,761.6	3,349.2
Growth (%)	1.3	15.7	10.4	21.3
Depreciation	504.7	541.7	570.8	590.3
Interest	168.3	161.3	241.5	159.0
Other Income	165.6	208.9	244.6	280.2
PBT	1,654.3	2,007.0	2,193.9	2,880.1
Total Tax	400.0	439.6	526.5	691.2
PAT before MI	1,254.2	1,567.4	1,667.4	2,188.9
Minority Interest	73.5	61.5	66.7	87.6
Adjusted PAT	1,180.8	1,505.9	1,600.7	2,101.3
Growth (%)	-15.0	27.5	6.3	31.3
EPS (Adjusted)	14.7	18.8	19.9	26.2

Source: Company, ICICIdirect.com Research

Balance sheet				₹ Crore			
(Year-end March)	FY15	FY16E	FY17E	FY18E			
Equity Capital	160.6	160.7	160.7	160.7			
Reserve and Surplus	10,640.9	11,696.7	13,035.4	14,792.8			
Total Shareholders funds	10,801.5	11,857.4	13,196.1	14,953.5			
Total Debt	1,703.3	5,191.4	4,391.4	2,891.4			
Deferred Tax Liability	284.6	447.3	472.3	522.3			
Long Term Provision	160.4	144.7	164.7	184.7			
MI & Other Liabilities	221.1	312.4	379.1	466.7			
Source of Funds	13,170.9	17,953.2	18,603.6	19,018.5			
Gross Block	7,003.1	8,031.5	8,781.5	9,081.5			
Accumulated Depreciation	2,731.9	3,273.6	3,844.4	4,434.7			
Net Block	4,271.2	4,758.0	4,937.2	4,646.9			
Capital WIP	580.9	809.3	759.3	789.3			
Fixed Assets	4,852.1	5,567.3	5,696.5	5,436.2			
Investments	639.8	756.9	539.8	639.8			
Goodwill on Consolidation	2,558.5	5,511.4	5,511.4	5,511.4			
Long term Loans & Advances	297.0	590.9	660.9	740.9			
Other Non current assets	121.7	123.7	163.7	203.7			
Inventory	3,780.6	3,808.0	4,719.3	5,406.5			
Debtors	2,004.3	2,359.3	2,660.0	3,047.3			
Loans and Advances	707.4	958.0	1,061.6	1,165.2			
Other Current Assets	144.9	264.9	274.4	283.9			
Cash	564.3	871.4	863.3	490.4			
Total Current Assets	7,201.4	8,261.6	9,578.7	10,393.3			
Creditors	1,577.2	1,409.5	1,716.1	1,966.0			
Provisions	420.2	506.1	544.2	594.1			
Other current libilities	502.1	1,023.8	1,083.4	1,143.0			
Total Current Liabilities	2,499.6	2,939.4	3,343.7	3,703.1			
Net Current Assets	4,701.9	5,322.2	6,235.0	6,690.2			
Application of Funds	13,170.9	17,872.3	18,807.1	19,222.0			

Source: Company, ICICIdirect.com Research

ash flow statement				₹ Crore
(Year-end March)	FY15	FY16E	FY17E	FY18
Profit/(Loss) after taxation	1,180.8	1,505.9	1,600.7	2,101.3
Add: Depreciation	504.7	541.7	570.8	590.
(inc)/Dec in Current Assets	-1,472.4	-753.1	-1,325.1	-1,187.
inc/(Dec) in Current Liabilities	866.0	439.8	404.3	359.
Others	168.3	161.3	241.5	159.
CF from Operating activities	1,247.4	1,895.7	1,492.2	2,022.
Change In Investment	68.8	-117.1	217.1	-100.
Purchase)/Sale of Fixed Assets	-1,024.3	-4,209.8	-700.0	-330.
Others	93.8	-21.8	1.7	37.
CF from Investing activities	-861.8	-4,348.7	-481.2	-392.
Change in Equity	0.0	0.0	0.0	0.
Change in Loan	455.4	3,488.1	-800.0	-1,500.
Dividend & Dividend tax	-193.3	-246.5	-262.0	-343.
Others	-294.4	-161.3	-241.5	-159.
CF from Financing activities	-32.2	3,080.2	-1,303.5	-2,003.
Net Cash Flow	353.4	627.2	-292.5	-372.
Cash and Cash equ. at beginning	175.2	528.6	1,155.8	863.
Cash	528.6	1,155.8	863.3	490.
Free Cash Flow	223.1	-2,314.1	792.2	1,692.

Source: Company, ICICIdirect.com Research

(Year-end March)	FY15	FY16E	FY17E	FY18E
Per share data (₹)				
Adjusted EPS	14.7	18.8	19.9	26.2
BV per share	134.5	147.7	164.4	186.2
Cash per Share	7.0	10.9	10.8	6.1
Dividend per share	2.4	3.1	3.3	4.3
Operating Ratios (%)				
Gross Margins	63.1	62.6	63.8	63.0
EBITDA margins	19.1	18.3	17.1	18.1
PAT Margins	10.4	11.0	9.9	11.4
Inventory days	121.6	101.6	106.8	106.8
Debtor days	64.5	63.0	60.2	60.3
Creditor days	50.7	37.6	38.8	38.
Asset Turnover	0.9	0.8	0.9	1.0
EBITDA convsion rate	57.7	75.8	54.0	60.
Return Ratios (%)				
RoE	10.9	12.7	12.1	14.
RoCE	13.8	12.1	13.1	16.
RoIC	14.2	12.3	13.1	15.
Valuation Ratios (x)				
P/E	32.0	25.1	23.6	18.
ev / Ebitda	17.8	16.7	14.8	11.
EV / Net Sales	3.4	3.0	2.5	2.3
Market Cap / Sales	3.3	2.8	2.3	2.0
Price to Book Value	3.5	3.2	2.9	2.
Solvency Ratios				
Debt / EBITDA	0.8	2.1	1.6	0.
Debt / Equity	0.2	0.4	0.3	0.
Current Ratio	2.7	2.5	2.6	2.
Quick Ratio	1.1	1.2	1.2	1.:



ICICIdirect.com coverage universe (Healthcare)

Company	I-Direct	CMP	TP	Rating	М Сар		EPS (₹)			PE(x)		EV/	'EBITDA	(x)		RoCE (%)		RoE (%)	
	Code	(₹)	(₹)		(₹ Cr)	FY15	FY16E	FY17E	FY15	FY16E	FY17E	FY15	FY16E	FY17E	FY15	FY16E	FY17E	FY15	FY16E	FY17
Ajanta Pharma	AJAPHA	1467	1,780	Buy	12911.2	36.0	45.7	52.4	40.7	32.1	28.0	26.8	23.3	19.9	50.3	43.7	37.9	37.8	34.4	30.0
Apollo Hospitals	APOHOS	1363	1,420	Hold	18955.1	23.7	27.6	34.6	57.4	49.4	39.3	27.6	23.9	18.9	9.9	11.2	13.0	10.4	11.1	12.5
Aurobindo Pharma	AURPHA	727	990	Buy	42541.8	28.1	33.9	37.7	25.9	21.4	19.3	30.7	25.1	22.0	23.4	24.7	25.0	31.7	28.7	24.7
Alembic Pharma	ALEMPHA	542	620	Hold	10219.5	15.1	38.2	19.6	35.9	14.2	27.6	32.2	12.6	23.9	30.7	58.0	24.8	32.1	51.5	22.3
Biocon	BIOCON	642.9	560	Hold	12857.0	20.4	22.1	28.3	31.5	29.1	22.7	8.3	7.6	6.4	10.4	9.1	10.9	12.5	10.9	12.7
Cadila Healthcare	CADHEA	318	390	Buy	32570.4	11.2	15.0	15.5	28.4	21.3	20.5	20.3	14.5	14.4	20.7	27.9	24.6	27.0	28.6	24.4
Cipla	CIPLA	470	470	Hold	39763.1	14.7	18.8	19.9	32.0	25.1	23.6	17.8	16.7	14.8	13.8	12.1	13.1	10.9	12.7	12.1
Divi's Laboratories	DIVLAB	1032	1,320	Buy	27383.1	32.1	40.2	46.7	32.2	25.7	22.1	22.3	18.7	15.9	29.4	31.3	31.1	24.4	25.6	25.1
Dr Reddy's Labs	DRREDD	2974	3,480	Buy	51613.1	129.0	142.1	139.2	23.0	20.9	21.4	14.4	12.6	12.3	16.7	15.1	15.1	22.3	18.9	16.1
Glenmark Pharma	GLEPHA	858	1,000	Buy	24229.6	23.1	32.2	41.4	37.1	26.7	20.7	22.2	16.8	13.8	13.3	16.2	18.8	21.7	21.2	21.7
Indoco Remedies	INDREM	263.2	390	Buy	2424.9	9.0	9.3	15.6	29.3	28.4	16.9	15.9	14.8	10.7	16.4	15.4	22.2	16.0	14.7	20.8
Ipca Laboratories	IPCLAB	440	515	Hold	5552.8	19.9	12.1	24.7	22.1	36.4	17.8	13.5	18.2	12.2	11.5	6.7	11.7	11.4	6.6	12.2
Jubilant Life Sciences	VAMORG	355.2	405	Buy	5657.5	-0.6	26.0	41.2	NA	13.7	8.6	14.6	7.1	5.7	5.8	13.2	16.2	NA	14.2	18.7
Lupin	LUPIN	1466	1,850	Buy	66060.9	53.6	50.4	66.0	27.3	29.1	22.2	18.3	19.8	13.8	35.1	18.6	22.5	27.1	20.7	22.1
Natco Pharma	NATPHA	447.4	630	Buy	7791.7	8.3	7.5	11.6	53.8	60.0	38.4	35.3	29.3	21.6	15.4	13.0	16.5	17.9	10.0	13.8
Sun Pharma	SUNPHA	773	845	Hold	185994.0	19.8	23.6	28.4	39.0	32.7	27.2	24.1	21.2	17.7	18.8	20.0	21.1	18.6	18.8	19.1
Syngene International	SYNINT	399	445	Buy	7971.0	8.8	11.1	15.6	43.3	34.2	24.3	26.6	20.9	17.0	19.5	13.3	16.7	20.7	21.2	23.5
Torrent Pharma	TORPHA	1356	1,650	Buy	22944.5	44.4	115.5	67.8	30.6	11.7	20.0	23.7	8.0	13.5	20.1	51.1	27.0	30.2	57.7	27.0
Unichem Laboratories	UNILAB	267.7	310	Buy	2431.9	8.3	12.3	15.5	32.2	21.7	17.2	23.3	14.7	11.7	8.5	13.8	16.2	8.7	11.7	13.4
Source: Company ICICIo	lirect com Re	search																		



RATING RATIONALE

ICICIdirect.com endeavours to provide objective opinions and recommendations. Icician ect.com assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Strong Buy, Buy, Hold and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock.

Strong Buy: >15%/20% for large caps/midcaps, respectively, with high conviction; Buy: >10%/15% for large caps/midcaps, respectively; Hold: Up to +/-10%; Sell: -10% or more;



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICIdirect.com Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com



ANALYST CERTIFICATION

We /l, Siddhant Khandekar, CA INTER and Mitesh Shah, MS (finance), Nandan Kamat MBA Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & conditions and other disclosures:

ICICI Securities Limited is a Sebi registered Research Analyst having registration no. INH000000990. ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, *inter alia*, engaged in the business of stock brokering and distribution of financial products. ICICI Securities is a wholly-owned subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities of any companies that the analysts cover.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment decisions, based on their own investment receiving this report. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts have any material conflict of interest at the time of publication of this report.

It is confirmed that Siddhant Khandekar, CA INTER and Mitesh Shah, MS (finance), Nandan Kamat MBA, Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

It is confirmed that Siddhant Khandekar, CA INTER and Mitesh Shah, MS (finance), Nandan Kamat MBA, Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.